Sarepta Therapeutics, Inc. (NASDAQ: SRPT) is a prominent player in the biotechnology sector, primarily focusing on revolutionary treatments for rare diseases. Specializing in RNA-targeted therapeutics and gene therapies, the company has carved out a niche in treating Duchenne muscular dystrophy (DMD), a devastating muscle-wasting condition. Despite its groundbreaking work, the current financial landscape presents a mixed bag for potential investors.

**Financial Overview and Market Position**

With a market capitalization of $2.21 billion, Sarepta is a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts. The firm is at the forefront of developing innovative treatments like EXONDYS 51, VYONDYS 53, and…